微超声与磁共振/超声融合靶向活检诊断临床显著前列腺癌准确性的比较
在前瞻性收集的104例疑似前列腺癌患者中,比较微超声靶向活检与磁共振/超声融合靶向活检诊断临床显著前列腺癌的准确性。微超声对临床显著前列腺癌的敏感性为94%,阴性预测值为90%,阳性预测值为40%,特异性为28%。初步试验结果提示微超声可能提供额外信息,需进一步研究。
要点
- 微超声靶向活检诊断临床显著前列腺癌的敏感性为94%(33/35例正确识别)。
- 微超声的阴性预测值为90%,阳性预测值为40%,特异性为28%。
- 两种靶向活检技术各漏诊1例仅由系统活检诊断的临床显著前列腺癌。
核心结论
- 根据初步试验结果,微超声可能为疑似前列腺癌患者提供关于临床显著前列腺癌存在与否的额外信息。
- 需进一步研究探讨这一新影像模态如何最好地应用于前列腺癌诊断路径。
研究设计与样本
- 前瞻性收集的104例疑似前列腺癌患者队列,根据前列腺特异性抗原、直肠指检及多参数磁共振至少一个PI-RADS≥3病灶定义疑似前列腺癌。
- 以微超声靶向活检为指标试验,磁共振/超声融合靶向活检为参考标准试验,比较检测临床显著前列腺癌(Gleason≥7)的诊断准确性。
主要发现
- 104例中诊断前列腺癌56例(54%),临床显著前列腺癌35例(34%)。
- 微超声检测临床显著前列腺癌的敏感性为94%,33/35例临床显著前列腺癌被正确识别。
- 微超声的阴性预测值为90%,阳性预测值为40%,特异性为28%。
- 微超声与多参数磁共振一致的61个靶向区域中,24个为临床显著前列腺癌。
- 不一致的靶向病灶中,微超声发现临床显著前列腺癌3例,多参数磁共振发现4例;两种技术均漏诊1例仅由系统活检诊断的临床显著前列腺癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称该结果为初步试验结果。
- 原文结论指出需进一步研究探讨该新影像模态在前列腺癌诊断路径中的最佳应用方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiparametric magnetic resonance imaging (mpMRI) and MRI/ultrasound (US) fusion targeted biopsies are an increasingly popular alternative to randomized biopsies, but adoption of this technique has been limited owing to its additional costs and complexity. High-resolution micro-ultrasound (micro-US) is a real-time US-based imaging modality that allows real-time targeted prostate biopsies using the Prostate Risk Identification Using Micro-Ultrasound risk identification protocol. We compared the diagnostic accuracy of micro-US targeted biopsies (index test) and MRI/US fusion targeted biopsies (reference standard test) in detecting clinically significant prostate cancer (csPC), defined as Gleason ≥7 disease, in a prospectively collected cohort of 104 patients with suspected PC defined according to prostate-specific antigen, digital rectal examination, and the presence of at least one Prostate Imaging-Reporting and Data System ≥3 lesion at mpMRI. PC was diagnosed in 56 patients (54%) and csPC in 35 (34%). Micro-US sensitivity for csPC detection was 94%, with 33/35 csPC cases correctly identified. The negative predictive value was 90%, while the positive predictive value was 40% and the specificity was 28%. Of the 61 targeted zones concordant between micro-US and mpMRI, 24 were csPC. Discordant targeted lesions led to csPC discovery by micro-US in three cases and mpMRI in four cases. Both techniques missed one case for which csPC was diagnosed by systematic biopsies only. PATIENT SUMMARY: According to the results of our preliminary trial, micro-ultrasound may provide additional information regarding the presence or absence of clinically significant prostate cancer (PC) in patients with suspected PC. Further studies are warranted to investigate how this new imaging modality can best be leveraged within the PC diagnostic pathway.
引用
- Lughezzani G, Saita A, Lazzeri M, et al. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31200848. doi:10.1016/j.euo.2018.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。